Compared with a similar population of patients with advanced HCC receiving first-line therapy with lenvatinib plus pembrolizumab in the Phase Ib Keynote 524 study, a higher proportion of those in the present study were HBsAg positive (85 vs. 19%), had AFP ≥400 ng/mL (65 vs. 30%), BCLC Stage C disease (76.7 vs. 71%) and MVTT (50 vs. 30%) [25]. Here, AFP is linked to hepatocellular carcinoma.